Table 2 Country-specific distribution of OAC and antiplatelet therapies.

From: Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey

 

Total

Albania

B&H

Bulgaria

Croatia

Montenegro

Romania

Serbia

n = 2663

n = 313

n = 265

n = 443

n = 159

n = 102

n = 699

n = 682

No antithrombotic therapy (%)

264 (9.9)

23 (7.3)

28 (10.6)

46 (10.4)

15 (9.4)

11 (10.8)

67 (9.6)

74 (10.9)

Oral anticoagulant therapy-overall (%)

1960 (73.6)

229 (73.2)

133 (50.2)

319 (72.0)

134 (84.3)

72 (70.6)

534 (76.4)

539 (79.0)

VKAs (%)

1662 (60.9)

205 (65.5)

111 (41.9)

191 (43.1)

110 (69.2)

68 (66.7)

482 (69.0)

455 (66.7)

NOACs (%)

338 (12.7)

24 (7.7)

22 (8.3)

128 (28.9)

24 (15.1)

4 (3.9)

52 (7.4)

84 (12.3)

Oral anticoagulant therapy alone (%)

1637 (61.5)

162 (51.8)

124 (46.8)

286 (64.6)

121 (76.1)

50 (49.0)

446 (63.8)

448 (65.7)

Antiplatelet therapy (%)

762 (28.6)

128 (40.9)

113 (42.6)

111 (25.1)

23 (14.5)

41 (40.2)

186 (26.6)

160 (23.5)

Single antiplatelet drug only (%)

320 (12.0)

39 (12.5)

88 (33.2)

54 (12.2)

9 (5.7)

14 (13.7)

61 (8.7)

55 (8.1)

DAPT only (%)

119 (4.5)

22 (7.0)

16 (6.0)

24 (5.4)

1 (0.6)

5 (4.9)

37 (5.3)

14 (2.1)

Dual therapya

240 (9.0)

51 (16.3)

9 (3.4)

17 (3.8)

9 (5.7)

14 (13.7)

74 (10.6)

66 (9.7)

Triple therapyb

83 (3.1)

16 (5.1)

0 (0.0)

16 (3.6)

4 (2.5)

8 (7.8)

14 (2.0)

25 (3.7)

  1. B&H: Bosnia & Herzegovina; OAC: oral anticoagulant; VKA: vitamin-K antagonist; NOAC: non-vitamin K antagonist; DAPT: dual antiplatelet therapy.
  2. aDual therapy: OAC plus single antiplatelet agent.
  3. bTriple therapy: OAC plus dual antiplatelet therapy.